| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 96361 |
Intravenous infusion, hydration; each additional hour |
2,761 |
2,156 |
$257K |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
4,587 |
3,971 |
$166K |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
3,064 |
2,713 |
$144K |
| 80053 |
Comprehensive metabolic panel |
6,893 |
5,546 |
$143K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
3,832 |
3,145 |
$121K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
1,488 |
1,255 |
$93K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
1,906 |
1,394 |
$82K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
1,509 |
1,144 |
$81K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
9,447 |
7,250 |
$62K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
3,137 |
2,277 |
$60K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
1,148 |
1,010 |
$58K |
| 70450 |
Computed tomography, head or brain; without contrast material |
1,568 |
1,333 |
$57K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
1,524 |
1,248 |
$54K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
938 |
817 |
$46K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
1,134 |
1,070 |
$41K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
4,722 |
3,693 |
$40K |
| 90853 |
Group psychotherapy (other than of a multiple-family group) |
2,962 |
375 |
$35K |
| 43239 |
Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple |
208 |
175 |
$33K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
497 |
417 |
$32K |
| 81003 |
|
1,802 |
1,548 |
$29K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
663 |
375 |
$27K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
2,667 |
718 |
$27K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
1,025 |
773 |
$26K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
779 |
492 |
$25K |
| 82962 |
|
2,345 |
1,208 |
$18K |
| 84484 |
|
2,335 |
1,815 |
$17K |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
1,258 |
1,067 |
$17K |
| 81025 |
|
1,836 |
1,592 |
$16K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
1,948 |
520 |
$16K |
| 84443 |
Thyroid stimulating hormone (TSH) |
1,477 |
1,262 |
$16K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
298 |
268 |
$15K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
518 |
402 |
$15K |
| 83880 |
|
710 |
585 |
$13K |
| 87077 |
|
810 |
708 |
$10K |
| 85610 |
|
1,928 |
1,423 |
$10K |
| 86850 |
|
406 |
340 |
$9K |
| 83690 |
|
1,905 |
1,626 |
$9K |
| G0378 |
Hospital observation service, per hour |
1,018 |
687 |
$9K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
1,333 |
1,153 |
$9K |
| 71046 |
Radiologic examination, chest; 2 views |
993 |
866 |
$8K |
| 81001 |
|
2,865 |
2,457 |
$8K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
883 |
499 |
$7K |
| 83735 |
|
1,645 |
1,090 |
$6K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
263 |
220 |
$6K |
| 83605 |
|
1,031 |
849 |
$6K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
67 |
60 |
$5K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
181 |
160 |
$5K |
| 90791 |
Psychiatric diagnostic evaluation |
178 |
93 |
$5K |
| 80061 |
Lipid panel |
478 |
426 |
$5K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
181 |
160 |
$5K |
| H0005 |
Alcohol and/or drug services; group counseling by a clinician |
190 |
39 |
$5K |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
108 |
94 |
$5K |
| 85027 |
|
856 |
684 |
$5K |
| 90837 |
Psychotherapy, 53 minutes with patient |
498 |
113 |
$4K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
66 |
52 |
$3K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
549 |
459 |
$3K |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
1,066 |
996 |
$3K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
497 |
374 |
$3K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
4,596 |
3,744 |
$3K |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
149 |
126 |
$3K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
1,384 |
959 |
$3K |
| 80143 |
|
125 |
100 |
$3K |
| 45380 |
Colonoscopy, flexible; with biopsy, single or multiple |
15 |
15 |
$3K |
| 76830 |
Ultrasound, transvaginal |
65 |
54 |
$2K |
| 74018 |
|
146 |
130 |
$2K |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
91 |
82 |
$2K |
| 71045 |
Radiologic examination, chest; single view |
2,602 |
2,200 |
$2K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
120 |
106 |
$2K |
| 87634 |
|
43 |
41 |
$2K |
| 45385 |
Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) |
16 |
13 |
$2K |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
32 |
24 |
$2K |
| 86901 |
|
523 |
443 |
$2K |
| 87186 |
|
364 |
314 |
$2K |
| 76642 |
|
41 |
38 |
$1K |
| 86900 |
|
523 |
443 |
$1K |
| 93971 |
|
43 |
36 |
$1K |
| 84702 |
|
86 |
50 |
$1K |
| 82728 |
|
71 |
66 |
$1K |
| 73630 |
|
247 |
195 |
$1K |
| 85379 |
|
160 |
138 |
$1K |
| 72125 |
Computed tomography, cervical spine; without contrast material |
141 |
111 |
$1K |
| 86780 |
|
106 |
78 |
$977.57 |
| 80179 |
|
125 |
101 |
$972.39 |
| 88175 |
Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer |
45 |
42 |
$969.14 |
| 87070 |
|
88 |
72 |
$961.52 |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
206 |
174 |
$927.10 |
| 71250 |
|
28 |
24 |
$911.29 |
| 86803 |
|
85 |
75 |
$887.93 |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
3,625 |
2,936 |
$834.95 |
| 87624 |
Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types |
26 |
25 |
$786.46 |
| 84439 |
|
83 |
73 |
$763.01 |
| 87340 |
|
63 |
57 |
$582.74 |
| 83540 |
|
57 |
52 |
$573.52 |
| 96375 |
Therapeutic injection; each additional sequential IV push |
2,116 |
1,649 |
$564.76 |
| 86140 |
|
160 |
118 |
$451.30 |
| 36415 |
Collection of venous blood by venipuncture |
5,736 |
3,990 |
$444.01 |
| 76770 |
|
14 |
12 |
$425.13 |
| 82565 |
|
17 |
12 |
$413.89 |
| 86762 |
|
29 |
27 |
$406.73 |
| 99215 |
Prolong outpt/office vis |
13 |
12 |
$402.54 |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
1,359 |
1,135 |
$385.67 |
| 83550 |
|
53 |
48 |
$365.52 |
| 94060 |
|
41 |
40 |
$339.07 |
| 87040 |
|
47 |
36 |
$328.03 |
| J2704 |
Injection, propofol, 10 mg |
1,877 |
1,454 |
$308.09 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
2,205 |
1,839 |
$223.41 |
| Q3014 |
Telehealth originating site facility fee |
15 |
14 |
$162.12 |
| 82607 |
|
26 |
24 |
$159.08 |
| 94729 |
|
37 |
37 |
$149.29 |
| 87205 |
|
65 |
53 |
$144.80 |
| 87081 |
|
30 |
26 |
$132.00 |
| 80329 |
|
134 |
80 |
$115.92 |
| 85730 |
|
35 |
32 |
$109.10 |
| 85018 |
|
63 |
52 |
$86.89 |
| 97162 |
|
16 |
14 |
$84.38 |
| 83516 |
|
22 |
12 |
$76.34 |
| 99152 |
|
196 |
169 |
$70.57 |
| 86592 |
|
13 |
12 |
$66.70 |
| 85652 |
|
33 |
29 |
$62.13 |
| 90686 |
|
116 |
84 |
$60.25 |
| 94726 |
|
12 |
12 |
$52.02 |
| 80047 |
|
13 |
12 |
$49.39 |
| 85007 |
|
37 |
27 |
$48.12 |
| 88342 |
|
45 |
31 |
$36.19 |
| 82043 |
|
15 |
15 |
$35.27 |
| 80320 |
|
554 |
482 |
$31.69 |
| 90674 |
|
58 |
45 |
$25.40 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
2,649 |
1,943 |
$18.53 |
| 96376 |
|
623 |
346 |
$17.71 |
| 73564 |
|
12 |
12 |
$16.88 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
2,029 |
1,616 |
$12.04 |
| A9270 |
Non-covered item or service |
8,927 |
2,505 |
$9.66 |
| 99153 |
Mod sedat endo service >5yrs |
370 |
320 |
$6.77 |
| 36416 |
|
1,307 |
1,050 |
$5.28 |
| J1170 |
Injection, hydromorphone, up to 4 mg |
364 |
242 |
$2.78 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
975 |
792 |
$2.19 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
2,352 |
1,852 |
$1.47 |
| J0690 |
Injection, cefazolin sodium, 500 mg |
901 |
679 |
$1.43 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
276 |
225 |
$1.18 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
161 |
111 |
$0.00 |
| G8979 |
Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
51 |
39 |
$0.00 |
| G1004 |
Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program |
39 |
29 |
$0.00 |
| G8978 |
Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals |
52 |
39 |
$0.00 |
| J3475 |
Injection, magnesium sulfate, per 500 mg |
31 |
12 |
$0.00 |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
100 |
63 |
$0.00 |
| G0008 |
Administration of influenza virus vaccine |
177 |
129 |
$0.00 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
146 |
83 |
$0.00 |
| J7060 |
5% dextrose/water (500 ml = 1 unit) |
37 |
25 |
$0.00 |
| J1815 |
Injection, insulin, per 5 units |
98 |
25 |
$0.00 |
| J2060 |
Injection, lorazepam, 2 mg |
30 |
24 |
$0.00 |
| J1642 |
Injection, heparin sodium, (heparin lock flush), per 10 units |
22 |
13 |
$0.00 |